Twitxy Saved

Molly Li

@mollylisc

Badminton player and medical oncologist in CUHK working on lung cancer screening and therapeutic development
Hong Kong Joined August 2022
219 Following 293 Followers 338 Posts

Latest posts 5

Molly Li @mollylisc
Please to host the latest IASLC podcast in Cantonese and to have key investigators of CROWN and LORIN study @TonyMok9 @iseeyouicu @AndersonChao511 to share with us their insights and future hopes in ALK positive lung cancer! A very interesting talk!
@IASLC #LCSM
IASLC Verified account @IASLC Aug 16
🎧 New #LungCancerConsidered episode in Cantonese!

@mollylisc is joined by Professor Mok Shu Kam Tony, @AndersonChao511 and @iseeyouicu to discuss advances in ALK+ non-small cell lung cancer.

Listen now: bit.ly/4wuhXZT

#LungCancer #Cantonese #ALK #China #NSCLC
View quoted post on X
0 replies 3 reposts 10 likes 3.5K views View on X
Molly Li @mollylisc
Sharing latest IASLC Podcast in Cantonese with CTS experts @CalvinSHNg & Prof Shuben Li on advances in surg techs in lung cancer, covering VATS, sublobar resection, endobronchial ablation & tubeless anesthesia. Learnt a lot from the discussion! @IASLC

iaslc.org/iaslc-news/lun…
www.iaslc.org LCC in Cantonese: Updates in Surgical Approaches and Techniques in Early-Stage Lung Cancer | IASLC As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with two expert card ...
Molly Li @mollylisc
Agree. Taking EGFR TKI as an example, none of the first generation EGFR TKIs showed positive OS, yet none would deny it being one of the greatest advances in lung cancer therapeutic development
Vivek Subbiah, MD Verified account @VivekSubbiah Feb 6
🚨⭐️Sharing our comment just published @TheLancetOncol @TheLancet "Factors that can make overall survival unreliable as a clinical trial outcome" - The Lancet Oncology @OncoAlert @oncodaily @Dr_R_Kurzrock
thelancet.com/journals/lanon…
View quoted post on X
Molly Li @mollylisc
Thanks @StephenVLiu for highlighting our study!
Stephen V Liu, MD Verified account @StephenVLiu Nov 1, 2025
Real world outcomes with first-line osimertinib in #EGFR NSCLC @LungCaJournal from @TonyMok9 @mollylisc show that for 37% of pts, progression is oligoprogressive and those pts have a longer time to treatment failure (26 vs 14m) and OS (35 vs 25m).

lungcancerjournal.info/article/S0169-…
View quoted post on X